{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:44:33Z","timestamp":1778899473038,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.clinthera.2010.06.015","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T08:53:18Z","timestamp":1279270398000},"page":"1015-1032","source":"Crossref","is-referenced-by-count":28,"title":["Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: A clinical review"],"prefix":"10.1016","volume":"32","author":[{"given":"Carrie","family":"Nemerovski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Hutchinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.06.015_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","article-title":"Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide","volume":"50","author":"Shoaf","year":"2007","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib2","series-title":"Canong's Review of Medical Physiology","author":"Barrett","year":"2009"},{"key":"10.1016\/j.clinthera.2010.06.015_bib3","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: The vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.06.015_bib4","series-title":"Samsca (tolvaptan) [prescribing Information]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.06.015_bib5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.06.015_bib6","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharma-cokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib7","series-title":"Red Book August 2009 Update","year":"2009"},{"key":"10.1016\/j.clinthera.2010.06.015_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.fjc.0000180899.24865.b6","article-title":"Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure","volume":"46","author":"Hauptman","year":"2005","journal-title":"J Cardiovasc Pharmacol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib9","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.06.015_bib10","first-page":"S57","article-title":"Effect of ketoconazole and grapefruit juice, CYP3A4 inhibitors, on the pharmaco-kinetics of tolvaptan, a non-peptide vasopressin antagonist","volume":"83","author":"Shoaf","year":"2008","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.06.015_bib11","first-page":"S57","article-title":"Effect of rifampin, CYP3A4 inducer, on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide vasopressin antagonist","volume":"83","author":"Mallikaarjun","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.06.015_bib12","doi-asserted-by":"crossref","first-page":"P37","DOI":"10.1016\/j.clpt.2003.11.139","article-title":"Lack of clinically significant interaction between steady state tolvaptan and digoxin in healthy volunteers","volume":"75","author":"Shoaf","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.06.015_bib13","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib14","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.06.015_bib15","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.3949\/ccjm.73.Suppl_3.S24","article-title":"AVP receptor antagonists as aquaretics: Review and assessment of clinical data","volume":"73","author":"Verbalis","year":"2006","journal-title":"Cleve Clin J Med."},{"key":"10.1016\/j.clinthera.2010.06.015_bib16","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2010.06.015_bib17","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA."},{"key":"10.1016\/j.clinthera.2010.06.015_bib18","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, doubleblind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib20","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Shortterm clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.06.015_bib21","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.06.015_bib22","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"14","year":"2005"},{"key":"10.1016\/j.clinthera.2010.06.015_bib23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2010.06.015_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: A new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am HeartJ."},{"key":"10.1016\/j.clinthera.2010.06.015_bib25","doi-asserted-by":"crossref","first-page":"8B","DOI":"10.1016\/j.amjcard.2005.03.003","article-title":"Neurohormonal activation in congestive heart failure and the role of vasopressin","volume":"95","author":"Chatterjee","year":"2005","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2005.11.005","article-title":"HFSA 2006 Comprehensive Heart Failure Practice Guideline","volume":"12","year":"2006","journal-title":"J Card Fail."},{"key":"10.1016\/j.clinthera.2010.06.015_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2010.06.015_bib28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib29","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med."},{"key":"10.1016\/j.clinthera.2010.06.015_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med."},{"key":"10.1016\/j.clinthera.2010.06.015_bib31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MNH.0b013e3283262ab0","article-title":"Advances in the pathogenesis and treatment of polycystic kidney disease","volume":"18","author":"Patel","year":"2009","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"10.1016\/j.clinthera.2010.06.015_bib33","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/01.ASN.0000028643.17901.42","article-title":"Genetics and pathogenesis of polycystic kidney disease","volume":"13","author":"Igarashi","year":"2002","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib34","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinthera.2010.06.015_bib35","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","author":"Hanaoka","year":"2000","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.clinthera.2010.06.015_bib36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway","volume":"57","author":"Yamaguchi","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinthera.2010.06.015_bib37","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T23:50:51Z","timestamp":1740268251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0149291810002067"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.06.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}